| Renaissance Pharma |
| https://renaissancepharma.co.uk Direct contact link Novel antibody therapies for treating rare paediatric diseases. Our lead candidate the anti-GD2 antibody Hu14.18K322A showed significant improvement in clinical outcomes in children with high-risk neuroblastoma. Our Team includes: Lee Morley (Jazz EUSA Pharma Zeneus Cephalon) Simon Ball (Sigma Tau GSK) Jonathan Morgan Debra Nevin (Oxford Glycosciences UCB Lonza) Dee Athawal |  |
For a limited time, sign up to our Starter Plan for $4.99 a month to unhide all information about the company.